{"id":{"repo_id":"strathclyde","oai_identifier":"oai:strathclyde:8c97kq46t"},"canonical_url":"https://search.dev.ndltd.org/etd/strathclyde/oai:strathclyde:8c97kq46t","repository":{"repo_id":"strathclyde","name":"University of Strathclyde","base_url":"https://stax.strath.ac.uk/catalog/oai"},"display":{"title":"Immunomodulatory effect of the Acanthocheilonema viteae product ES-62 in arthropod extract models of asthma","abstract":"Excretory Secretory (ES)-62 is a product of the helminth Acanthocheilonema viteae, a member of a group of parasites known to inhibit or modulate inflammation. ES-62 has been previously shown to inhibit ovalbumin (OVA)-induced airway allergy. Additionally, the small molecule analogue 12b based on the ES product has been found to alleviate inflammation in a house dust mite extract (HDME) allergy model.;The intention of this study was to identify whether ES-62 inhibits the induction of allergy in cockroach extract (CRE) and HDME models through the analysis of several key parameters of allergy induction. ES-62 displayed some immunomodulatory activity at 1 μg/dose in the CRE allergy model. Specifically, CRE allergy-amplified Interleukin-4 (Il4), Il13 and Ifng pulmonary gene expression was reduced with ES-62 treatment.;ES-62 also decreased the level of peribronchial inflammatory infiltrate and marginally reduced the Immunoglobulin G1 (IgG1) response to CRE. Essentially no activity was seen at 2 μg/dose of ES-62 in the same model; though whether this is due to a difference in composition of CRE extract employed remains to be clarified. ES-62 is also given as a therapeutic intranasally for the first time in mice with induced airway allergy.;In the second model employed, HDME allergy, phosphorylcholine-specific IgM antibodies were produced in the presence of ES-62 in combination with HDME but not HDME alone. ES-62 lacked efficacy in this model, though further work should be undertaken to investigate dosage alterations before final conclusions are drawn.","abstract_html":"Excretory Secretory (ES)-62 is a product of the helminth Acanthocheilonema viteae, a member of a group of parasites known to inhibit or modulate inflammation. ES-62 has been previously shown to inhibit ovalbumin (OVA)-induced airway allergy. Additionally, the small molecule analogue 12b based on the ES product has been found to alleviate inflammation in a house dust mite extract (HDME) allergy model.;The intention of this study was to identify whether ES-62 inhibits the induction of allergy in cockroach extract (CRE) and HDME models through the analysis of several key parameters of allergy induction. ES-62 displayed some immunomodulatory activity at 1 μg/dose in the CRE allergy model. Specifically, CRE allergy-amplified Interleukin-4 (Il4), Il13 and Ifng pulmonary gene expression was reduced with ES-62 treatment.;ES-62 also decreased the level of peribronchial inflammatory infiltrate and marginally reduced the Immunoglobulin G1 (IgG1) response to CRE. Essentially no activity was seen at 2 μg/dose of ES-62 in the same model; though whether this is due to a difference in composition of CRE extract employed remains to be clarified. ES-62 is also given as a therapeutic intranasally for the first time in mice with induced airway allergy.;In the second model employed, HDME allergy, phosphorylcholine-specific IgM antibodies were produced in the presence of ES-62 in combination with HDME but not HDME alone. ES-62 lacked efficacy in this model, though further work should be undertaken to investigate dosage alterations before final conclusions are drawn.","abstract_has_math":false,"creators":["Duncombe-Moore, Josephine"],"institution":"University of Strathclyde","degree_name":"mres","degree_level":"masters-pg","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2017,"date_issued":"2017","date_published":"2017","updated_at":"2026-07-24T04:45:26Z","subjects":[],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.doi","label":"DOI","values":["10.48730/s3ng-g304"],"render_values":[{"text":"10.48730/s3ng-g304","href":"https://doi.org/10.48730/s3ng-g304","code":true}]},{"key":"dc:identifier","label":"Identifier","values":["T14815"],"render_values":[{"text":"T14815","href":null,"code":true}]},{"key":"dc:creator.authoridentifier","label":"Author Identifier","values":["201554898"],"render_values":[{"text":"201554898","href":null,"code":true}]}]},"links":{"outbound_url":"https://stax.strath.ac.uk/concern/theses/8c97kq46t","outbound_label":"Repository record","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Duncombe-Moore, Josephine"]},{"key":"dc:creator.authoridentifier","label":"Author Identifier","values":["201554898"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2017"]},{"key":"dc:date.issued","label":"Date","values":["2017"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["Strathclyde Institute of Pharmacy and Biomedical Sciences"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Strathclyde"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["masters-pg"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["mres"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["T14815"]},{"key":"dc:identifier.doi","label":"DOI","values":["10.48730/s3ng-g304"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://stax.strath.ac.uk/concern/theses/8c97kq46t"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Excretory Secretory (ES)-62 is a product of the helminth Acanthocheilonema viteae, a member of a group of parasites known to inhibit or modulate inflammation. ES-62 has been previously shown to inhibit ovalbumin (OVA)-induced airway allergy. Additionally, the small molecule analogue 12b based on the ES product has been found to alleviate inflammation in a house dust mite extract (HDME) allergy model.;The intention of this study was to identify whether ES-62 inhibits the induction of allergy in cockroach extract (CRE) and HDME models through the analysis of several key parameters of allergy induction. ES-62 displayed some immunomodulatory activity at 1 μg/dose in the CRE allergy model. Specifically, CRE allergy-amplified Interleukin-4 (Il4), Il13 and Ifng pulmonary gene expression was reduced with ES-62 treatment.;ES-62 also decreased the level of peribronchial inflammatory infiltrate and marginally reduced the Immunoglobulin G1 (IgG1) response to CRE. Essentially no activity was seen at 2 μg/dose of ES-62 in the same model; though whether this is due to a difference in composition of CRE extract employed remains to be clarified. ES-62 is also given as a therapeutic intranasally for the first time in mice with induced airway allergy.;In the second model employed, HDME allergy, phosphorylcholine-specific IgM antibodies were produced in the presence of ES-62 in combination with HDME but not HDME alone. ES-62 lacked efficacy in this model, though further work should be undertaken to investigate dosage alterations before final conclusions are drawn."]},{"key":"dc:description.abstract","label":"Abstract","values":["Excretory Secretory (ES)-62 is a product of the helminth Acanthocheilonema viteae, a member of a group of parasites known to inhibit or modulate inflammation. ES-62 has been previously shown to inhibit ovalbumin (OVA)-induced airway allergy. Additionally, the small molecule analogue 12b based on the ES product has been found to alleviate inflammation in a house dust mite extract (HDME) allergy model.;The intention of this study was to identify whether ES-62 inhibits the induction of allergy in cockroach extract (CRE) and HDME models through the analysis of several key parameters of allergy induction. ES-62 displayed some immunomodulatory activity at 1 μg/dose in the CRE allergy model. Specifically, CRE allergy-amplified Interleukin-4 (Il4), Il13 and Ifng pulmonary gene expression was reduced with ES-62 treatment.;ES-62 also decreased the level of peribronchial inflammatory infiltrate and marginally reduced the Immunoglobulin G1 (IgG1) response to CRE. Essentially no activity was seen at 2 μg/dose of ES-62 in the same model; though whether this is due to a difference in composition of CRE extract employed remains to be clarified. ES-62 is also given as a therapeutic intranasally for the first time in mice with induced airway allergy.;In the second model employed, HDME allergy, phosphorylcholine-specific IgM antibodies were produced in the presence of ES-62 in combination with HDME but not HDME alone. ES-62 lacked efficacy in this model, though further work should be undertaken to investigate dosage alterations before final conclusions are drawn."]},{"key":"dc:title","label":"Title","values":["Immunomodulatory effect of the Acanthocheilonema viteae product ES-62 in arthropod extract models of asthma"]}]}],"canonical_facts":{"dc:creator":["Duncombe-Moore, Josephine"],"dc:creator.authoridentifier":["201554898"],"dc:date":["2017"],"dc:date.issued":["2017"],"dc:description":["Excretory Secretory (ES)-62 is a product of the helminth Acanthocheilonema viteae, a member of a group of parasites known to inhibit or modulate inflammation. ES-62 has been previously shown to inhibit ovalbumin (OVA)-induced airway allergy. Additionally, the small molecule analogue 12b based on the ES product has been found to alleviate inflammation in a house dust mite extract (HDME) allergy model.;The intention of this study was to identify whether ES-62 inhibits the induction of allergy in cockroach extract (CRE) and HDME models through the analysis of several key parameters of allergy induction. ES-62 displayed some immunomodulatory activity at 1 μg/dose in the CRE allergy model. Specifically, CRE allergy-amplified Interleukin-4 (Il4), Il13 and Ifng pulmonary gene expression was reduced with ES-62 treatment.;ES-62 also decreased the level of peribronchial inflammatory infiltrate and marginally reduced the Immunoglobulin G1 (IgG1) response to CRE. Essentially no activity was seen at 2 μg/dose of ES-62 in the same model; though whether this is due to a difference in composition of CRE extract employed remains to be clarified. ES-62 is also given as a therapeutic intranasally for the first time in mice with induced airway allergy.;In the second model employed, HDME allergy, phosphorylcholine-specific IgM antibodies were produced in the presence of ES-62 in combination with HDME but not HDME alone. ES-62 lacked efficacy in this model, though further work should be undertaken to investigate dosage alterations before final conclusions are drawn."],"dc:description.abstract":["Excretory Secretory (ES)-62 is a product of the helminth Acanthocheilonema viteae, a member of a group of parasites known to inhibit or modulate inflammation. ES-62 has been previously shown to inhibit ovalbumin (OVA)-induced airway allergy. Additionally, the small molecule analogue 12b based on the ES product has been found to alleviate inflammation in a house dust mite extract (HDME) allergy model.;The intention of this study was to identify whether ES-62 inhibits the induction of allergy in cockroach extract (CRE) and HDME models through the analysis of several key parameters of allergy induction. ES-62 displayed some immunomodulatory activity at 1 μg/dose in the CRE allergy model. Specifically, CRE allergy-amplified Interleukin-4 (Il4), Il13 and Ifng pulmonary gene expression was reduced with ES-62 treatment.;ES-62 also decreased the level of peribronchial inflammatory infiltrate and marginally reduced the Immunoglobulin G1 (IgG1) response to CRE. Essentially no activity was seen at 2 μg/dose of ES-62 in the same model; though whether this is due to a difference in composition of CRE extract employed remains to be clarified. ES-62 is also given as a therapeutic intranasally for the first time in mice with induced airway allergy.;In the second model employed, HDME allergy, phosphorylcholine-specific IgM antibodies were produced in the presence of ES-62 in combination with HDME but not HDME alone. ES-62 lacked efficacy in this model, though further work should be undertaken to investigate dosage alterations before final conclusions are drawn."],"dc:identifier":["T14815"],"dc:identifier.doi":["10.48730/s3ng-g304"],"dc:identifier.uri":["https://stax.strath.ac.uk/concern/theses/8c97kq46t"],"dc:publisher.department":["Strathclyde Institute of Pharmacy and Biomedical Sciences"],"dc:publisher.institution":["University of Strathclyde"],"dc:title":["Immunomodulatory effect of the Acanthocheilonema viteae product ES-62 in arthropod extract models of asthma"],"dc:type.qualificationlevel":["masters-pg"],"dc:type.qualificationname":["mres"]},"updated_at":"2026-07-24T04:45:26Z"}